Blood-derived Eye Drops
Blood-derived Eye Drops - Related Videos
06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
0 Views •
Cited by 2 •
2020
We developed a simple flow cytometry assay for evaluating the binding of PD-1–blocking antibodies to T cells, requiring only a drop of peripheral blood from cancer patients.
07:21
An All-on-chip Method for Rapid Neutrophil Chemotaxis Analysis Directly from a Drop of Blood
0 Views •
Cited by 11 •
2017
This article provides the detailed method of performing a rapid neutrophil chemotaxis assay by integrating the on-chip neutrophil isolation from whole blood and the chemotaxis test on a single microfluidic chip.
10:52
Isolation of Blood-vessel-derived Multipotent Precursors from Human Skeletal Muscle
0 Views •
Cited by 22 •
2014
Blood vessels within human skeletal muscle harbor several multi-lineage precursor populations that are ideal for regenerative applications. This isolation method allows simultaneous purification of three multipotent precursor cell populations respectively from three structural layers of blood vessels: myogenic endothelial cells from intima, pericytes from media, and adventitial cells from adventitia.
02:18
Generation of Neuronal Cells from Blood-Derived Pluripotent Stem Cells
0 Views •
2025
This video demonstrates a technique to generate neuronal cells from blood-derived pluripotent stem cells (BD-PSCs). The BD-PSCs are obtained via reprogramming blood progenitor cells. The undifferentiated BD-PSCs are cultured on cell culture substrate-coated coverslips using a neural induction medium and a neural differentiation medium, triggering differentiation into cells with a neuronal phenotype.
07:53
Generating a Blood-Brain Barrier Chip Using iPSC-derived Precursor Cells
0 Views •
2025
This video showcases creating a blood-brain barrier chip using iPSC-derived precursor cells. It involves seeding neural progenitor cells and brain microvascular endothelial cells in separate channels with a porous membrane. By flowing differentiation media, the endothelial cells form tight junctions resembling blood vessels, and the neural cells mature into various brain cell types, establishing a functional blood-brain barrier on the chip.
FAQs
Different blood fractions contribute distinct biological material to the formulation. Processing may yield serum, plasma, or platelet-rich components, each carrying proteins, growth factors, and other molecules that contact the ocular surface. These constituents support lubrication, epithelial repair, and regulation of inflammation, giving clinicians options beyond the limited supportive role of conventional artificial tears.
The personalized source can make these drops relevant when a patient’s ocular surface does not respond adequately to standard artificial tears. Because the preparation is derived from the individual’s blood, it supplies biologic constituents associated with surface maintenance and repair rather than lubrication alone. This helps explain its role in severe or persistent ocular-surface problems.
Proteins, growth factors, and other molecules in the blood-derived preparation can support the ocular surface in two complementary ways. They may promote repair of damaged epithelium while also helping regulate inflammation. This combination is particularly relevant when surface injury or persistent epithelial disruption limits recovery and symptoms continue despite conventional supportive treatment.
Preparation starts with collecting the patient’s blood, followed by processing to separate a selected fraction such as serum, plasma, or platelet-rich material. That fraction is then formulated for topical ocular use. Because the final product is biologic and patient-derived, preparation requires controlled handling rather than the simple packaging process used for ordinary artificial tears.
Storage and treatment protocols require careful clinical control because these drops are biologic preparations made from blood. Appropriate control supports the intended use of the selected blood fraction and helps maintain a consistent treatment process. Clinicians therefore manage preparation, storage, and administration as connected parts of care rather than treating the drops as routine lubricants.
Clinicians may use them for severe dry eye, persistent corneal epithelial defects, or ocular-surface injury, particularly when conventional artificial tears do not provide sufficient relief. Their value comes from combining lubrication with biologic support for epithelial repair and inflammation regulation. These applications place the treatment within regenerative and supportive approaches to ocular-surface medicine.